Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

2 Dec 2022

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

Previous infection with SARS-CoV-2 and booster vaccination protect against ICU admission and mortality following infection with the Omicron variant.

1 Dec 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.

30 Nov 2022

Researchers use a comparative study to model RSV prevention in children

Using computational modeling, a new paper compares the benefit of maternal vaccines versus the administration of respiratory syncytial virus (RSV)-specific monoclonal antibody (mAb) therapy against RSV.

28 Nov 2022

Sino Biological announces construction of its new US-based center for bioprocessing

Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

From Sino Biological Inc. 24 Nov 2022

Plant-based monoclonal antibody increases potency of antibody cocktail against SARS-CoV-2 Omicron variant

A novel mAb against the SARS-CoV-2 RBD through a hybridoma technique, followed by chimerization and expression in plants.

22 Nov 2022

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

Researchers explored active and passive vaccination among children against respiratory syncytial virus (RSV).

22 Nov 2022

UC San Diego receives $8 million CIRM funding to expedite stem cell therapy clinical trials

Stem cells show particular promise in treating diseases for which few other effective treatments exist. In these therapies, stem cells are introduced into the body where they develop into specialized cells that repair, restore, replace or regenerate cells that have been damaged by the disease.

21 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

In a recent study published in the journal JAMA Network, researchers in the United States investigated factors that restricted the use of antivirals directed at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) between January and February 2022.

16 Nov 2022

Research findings could bolster the effectiveness of immune-checkpoint therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.

16 Nov 2022

Utilizing marine sources to extract DHA to treat Alzheimer’s

The anti-neurodegenerative effects of docosahexaenoic acid (DHA) and DHA-rich phospholipids (DH-PL) derived from fisheries and aquaculture byproducts.

15 Nov 2022

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab-;a human monoclonal antibody that targets the type I IFN receptor-;in patients with lupus.

14 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A new study investigated the impact of a monoclonal anti-thymic stromal lymphopoietin (TSLP) antibody on subcutaneous allergen immunotherapy (SCIT) efficacy among patients with allergic rhinitis.

3 Nov 2022

New control system could be used to finely tune the production of useful proteins

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

1 Nov 2022

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

New research discussed the structure and life cycle of respiratory syncytial virus (RSV), the current research on the treatment and prevention of RSV infections, and the advancements in RSV mRNA vaccine technology after the surge in vaccine research during the COVID-19 pandemic.

1 Nov 2022

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

31 Oct 2022

New insights on antibody response against SARS-CoV-2 Omiron sublineages

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).